Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.

Delforge, Michel;Vekemans, Marie-Christiane;Depaus, Julien;Meuleman, Nathalie;Anguille, Sébastien;et.al.
(2022) HemaSphere — Vol. 6, n° 12, p. e813 [1-4] (2022)

Files

DelforgeMHemasphere2022.pdf
  • Open Access
  • Adobe PDF
  • 773 KB
Download

Details

Authors
Show more
Abstract
(en) Multiple myeloma (MM) is a hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. Disease relapse frequently occurs, with treatment commonly involving sequential lines of treatment (LOT) including immunomodulatory agents (IMiD), proteasome inhibitors (PI), and monoclonal antibodies.[...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Delforge, M., Vekemans, M.-C., Depaus, J., Meuleman, N., Van de Velde, A., Vande Broek, I., Vandervennet, S., Van Hoorenbeeck, S., Moorkens, E., Strens, D., Diels, J., Ghilotti, F., Haefliger, B., Dalhuisen, S., Deraedt, W., & Anguille, S. (2022). Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice. HemaSphere, 6(12), e813 [1-4]. https://doi.org/10.1097/HS9.0000000000000813 (Original work published 2022)